HALB (Halberd) Research & Development: $ Mil (TTM As of Jul. 2023)


What is Halberd Research & Development?

Halberd HALB Research & Development is $ Mil as of Jul. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Halberd's Research & Development for the six months ended in Jul. 2023 was $0.30 Mil. Halberd does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Jul. 2023.

Halberd  (OTCPK:HALB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Halberd Research & Development Related Terms

Halberd Research & Development Historical Data

* Premium members only.

The historical data trend for Halberd's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Research & Development Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Research & Development
0.00 0.91 0.30

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Research & Development 0.00 0.91 0.30

Halberd Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
Halberd (HALB) has a Research & Development of $ Mil as of Jul. 2023. Research and development expense is the total cost for research and development activities. View historical data on Halberd and its competitors.
Is Halberd's Research & Development too high?
Halberd's current Research & Development is $ Mil.
How does Halberd's Research & Development compare to GRI and OCEA?
Halberd's Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Halberd and its competitors. Halberd's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Halberd (HALB), the current Research & Development is $ Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.